HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $20

Benzinga · 2d ago
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $27 to $20.